SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ADVENTRX Pharmaceuticals Inc (Anx)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: ggamer who wrote (103)5/22/2007 5:51:58 PM
From: Keith FeralRead Replies (1) of 418
 
There are 2 types of chemo - cytotoxic agents and leucovorin. The latter is used to deliver cytotoxins like 5FU which binds the drug to the enzymes in the cancer cells. However, leucovorin is a 50 year old generic drug which only provides very low concentrations of active folate - methylene tetrahyrdo folate. Cofactor provides a direct form of the folate in high concentration. Keep in mind that folate was discovered to treat anemia for pregnant women back in the 1940's.

Anyways, intravenous folate binds 5FU to the cancer cells to eliminate the replication of the cancer cells and causes the tumor cells to die. The high level of folate concentration binds more 5FU to the tumors. At the same time, it helps the healthy cells recover from toxic effects of the chemo drugs. In particular, intravenous folate helps the bone marrow recover from anemia.

Cofactor is replacing a existing technology with a much better delivery system. Intracellular concentrations of folate are measured 3 to 4 times greater with 60 mL bolus injections of Cofactor than 500 mL infusional dosages of leucovorin. The bolus injection takes 2 minutes to deliver and the infusional delivery of leucovorin takes 2 hours.

All of the preclinical and phase 1 and phase 2 results keep showing the value added benefit of Cofactor vs. leucovorin. I won't bother to go over all the stats, but if you visit the company's website there are plenty of slides. Go to the Investors page and view one of the investor slideshows from Rodman and Renshaw or one of the other presentations.

Chemo is never going to get phased out, and leucovorin is used in 80% of all first line chemo treatments for breast cancer, colon cancer, and almost every procedure. No one has ever bothered to come up with a better form of the drug before Adventrx, formerly BioKeys. They have absolutely nailed down this opportunity and managed to attract Icahn and his representatives to the company to provide private equity 2 years ago. They funded the secondary last year, so now all they need is the corporate partnership to take off to the next level.

If that isn't enough, the company has also discovered 4 other drugs that are entering registration trials this year. Save those for another post.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News